Compare PKBK & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PKBK | GOSS |
|---|---|---|
| Founded | 1999 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 269.2M | 726.8M |
| IPO Year | N/A | 2019 |
| Metric | PKBK | GOSS |
|---|---|---|
| Price | $25.32 | $3.56 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $8.60 |
| AVG Volume (30 Days) | 31.4K | ★ 3.2M |
| Earning Date | 01-23-2026 | 11-05-2025 |
| Dividend Yield | ★ 2.83% | N/A |
| EPS Growth | ★ 21.56 | N/A |
| EPS | ★ 2.83 | N/A |
| Revenue | ★ $71,766,000.00 | $44,051,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $6.41 |
| P/E Ratio | $8.97 | ★ N/A |
| Revenue Growth | ★ 13.64 | N/A |
| 52 Week Low | $16.94 | $0.76 |
| 52 Week High | $25.55 | $3.87 |
| Indicator | PKBK | GOSS |
|---|---|---|
| Relative Strength Index (RSI) | 80.07 | 61.72 |
| Support Level | $23.72 | $3.53 |
| Resistance Level | $24.11 | $3.87 |
| Average True Range (ATR) | 0.50 | 0.23 |
| MACD | 0.16 | 0.00 |
| Stochastic Oscillator | 84.58 | 64.80 |
Parke Bancorp Inc operates as a commercial bank providing personal and financial services to individuals and small to mid-sized businesses in various states of the USA. The bank offers services such as loan products, deposit services, and other financial products through its retail branches and other channels to its customers. Its lending businesses are commercial real estate lending, residential real estate lending, and construction lending among others. The Company operates one reportable segment of business, community banking.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.